Oct 22,2021

DTx company Click Therapeutic scores $52M in Series B funding

This morning prescription digital therapeutic company Click Therapeutic announced a $52 million Series B funding round. H.I.G. BioHealth Partners and Accelmed Partners ll led the round, with participation from Health Catalyst Capital, Revelation Partners, Sanofi, K2 HealthVentures, Hima Ventures and RdigetopHealth. This news comes over a year after the company inked a $500 million-plus deal with pharma company Boehringer Ingelheim to jointly commercialize a digital treatment for patients with schizophrenia.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Nov 10,2021

Survey: 58% of veterans with PTSD still struggle with symptoms after treatment, only 9% feel fully recovered

The online survey of 200 U.S. military veterans who have been diagnosed with PTSD was conducted by Freespira in recognition of Veterans Day. The results mirror peer-reviewed studies finding that up to two-thirds of veterans and military personnel who undergo standard psychotherapeutic treatment for PTSD still retain their diagnosis after treatment. Overall, only 9% of veterans surveyed say they have fully recovered from PTSD and no longer have symptoms.

View Analyst & Ambassador Comments
Go to original news
Nov 11,2021

AffaMed sets up digital medicines unit

AffaMed is advancing towards the addition and integration of digital therapeutics and diagnostics systems into its portfolio of solutions for eye, brain and mental health disorders. China-based biopharmaceutical firm AffaMed Therapeutics has established its digital medicines subsidiary, AffaMed Digital. Based on a press release, the newly formed unit will focus on developing and marketing evidence-based, clinically validated digital medicines to treat, diagnose, prevent and manage medical disorders or diseases, either as stand-alone novel treatment options or alongside other therapies.

View Analyst & Ambassador Comments
Go to original news
Nov 29,2021

ieso Raises $53 Million to Address Global Mental Health Crisis With Digital Therapeutics

ieso, a UK leader in digital mental healthcare, announces the completion of its $53 million Series B financing round led by investment firm Morningside, with further new investment from Sony Innovation Fund and existing shareholders IP Group, Molten Ventures and Ananda Impact Ventures.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Dec 07,2021

Limbix Raises $15 Million in Series A2 Financing

Today, Limbix, a prescription digital therapeutic company developing treatments for adolescent mental health disorders, announced it has raised $15 million in Series A2 financing from both existing and new investors, bringing total funding to date to $31 million. The round was led by GSR Ventures, with participation from existing investors Digital Garage, Storm Ventures, Bixink and DN Capital. Capital raised in the financing will be used by Limbix for commercialization efforts and to double its staff to approximately 60 employees by Q2, 2022. With an expanded product and research team, Limbix plans to accelerate the development and testing of new digital therapeutics targeting other common adolescent mental health disorders.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Dec 14,2021

HelloBetter Diabetes and Depression – new, highly effective, digital therapy option available on prescription in Germany

HelloBetter Diabetes and Depression, the first online therapy course for the treatment of depressive symptoms in people with type 1 and 2 diabetes, is now eligible for prescription and reimbursement. Physicians and psychotherapists can thus prescribe the Digital Health Application (“DiGA”) on prescription.

PRODUCT

#reimbursement

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 15,2021

Digital Therapy for Prenatal Insomnia May Prevent Postpartum Depression

A digital version of cognitive behavioral therapy, or dCBT, that previously had been shown to reduce insomnia during pregnancy may also prevent postpartum depression and reduce insomnia and anxiety in women up to six months after they give birth, according to a new study by researchers at UC San Francisco. The study, which appears in the current issue of the journal Sleep, is unique in showing that non-depressed women who received dCBT (Sleepio, by Big Health) for insomnia during pregnancy also slept better and had less depression several months into the postpartum period. The study is a follow-up to research that appeared January 2020 in JAMA Psychiatry showing the treatment reduced insomnia, depression, and anxiety symptoms during pregnancy.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Dec 16,2021

Pear Therapeutics Announces The Acquisition Of Two Assets Addressing A Comprehensive Spectrum Of Depression Conditions

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the continued development of its PDT product candidate pipeline. Pear acquired and/or licensed two new digital therapeutic assets, from Waypoint Health Innovations, LLC and a researcher named Fredrik Holländare of Örebro University, that are designed for the treatment of a spectrum of depression conditions. Pear intends to leverage these two new assets to expand its depression product candidate to treat mild, moderate, severe, and treatment-refractory depression.

PRODUCT

#cbt

#software

View Analyst & Ambassador Comments
Go to original news
Dec 16,2021

Smileyscope Takes its Virtual Reality Digital Therapeutics Platform to the Next Level With the Power of Mindfulness

Australia- and New York-based, Smileyscope Holding Inc (Smileyscope) is a global pioneer in virtual reality (VR) therapeutics, and they welcome the internationally renowned mindfulness thought leader Craig Hassed OAM onto its platform enabling users to enjoy the immersive power of meditation.

PRODUCT

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Dec 16,2021

Jolly Good to study VR therapy for chronic pain in Japan

Japanese medical device maker Jolly Good and the Pain Center at the Aichi Medical University Hospital will conduct a study on the efficacy of virtual reality-based therapy for chronic pain. It was in April last year that Jolly Good set up its digital therapeutics division, which involves a team of psychiatrists, pharmaceutical strategy specialists, and other DTx specialists. Through this, the company is expanding to cover multiple mental illnesses and lifestyle-related diseases. Jolly Good has been known for providing VR for medical training.

PRODUCT

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH